

1 The genetics of hereditary cancer risk syndromes 2 in Brazil: a comprehensive analysis of 1682 3 patients

4 5 Short running title: Cancer risk variants in 1682 Brazilians

6
7 Jarbas Maciel de Oliveira^{1,2*}, Nuria Bengala Zurro³, Antonio Victor Campos
8 Coelho³, Marcel Pinheiro Caraciolo³, Rodrigo Bertollo de Alexandre³, Murilo
9 Castro Cervato³, Renata Moldenhauer Minillo³, George de Vasconcelos
10 Carvalho Neto³, Ivana Grivicich² and João Bosco de Oliveira Filho^{3*}

11
12 ¹ Hospital Memorial Arcoverde, Arcoverde, Pernambuco, Brazil

13 ² Universidade Luterana do Brasil, Programa de Pós-graduação em Biologia
14 Celular e Molecular Aplicada à Saúde, Canoas, Rio Grande do Sul, Brazil

15 ³ Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil

16
17 * Corresponding author

18 jarbasmaciel@yahoo.com.br (JMO) or joao.bosco@einstein.br (JBOF)

19
20 **Conflicts of interest:** The authors declare that they have no conflict of interest.

21 **Data availability:** Data available within the article or its supplementary materials.

22 **Acknowledgements:** Funding: This research did not receive any specific grant
23 from funding agencies in the public, commercial, or not-for-profit sectors.

24

25 **Abstract**

26 Hereditary cancer risk syndromes are caused by germline variants. Most studies
27 on hereditary cancer have been conducted in white populations. We report the
28 largest study in Brazilian individuals with multiple ethnicities. We genotyped 1682
29 individuals from all regions of the country with Next-generation sequencing (NGS)
30 panels. Most were women with personal/family history of cancer, mostly breast
31 and ovarian. We identified 321 pathogenic/likely pathogenic (P/LP) variants in
32 305 people (18.1%) distributed among 32 genes. Most were on *BRCA1* and
33 *BRCA2* (129 patients, 26.2% and 14.3% of all P/LP, respectively), *MUTYH* (42
34 monoallelic patients, 13.1%), *PALB2* (25, 7.8%), Lynch syndrome genes (17,
35 5.3%), and *TP53* (17, 5.3%). Transheterozygosity prevalence in our sample was
36 0.89% (15/1682). *BRCA1/BRCA2* double heterozygosity rate was 0.78% (1/129)
37 for *BRCA* variants carriers and 0.06% (1/1682) overall. We evaluated the
38 performance of the genetic testing criteria by NCCN and Brazilian National Health
39 Agency (ANS). We observed false negative rates of 17.3% and 44.2%, meaning
40 that both failed to detect a substantial part of P/LP positive patients. Our results
41 add knowledge on the Brazilian spectrum of cancer risk germline variants,
42 demonstrate that large multigene panels have high rates of positivity, and indicate
43 that Brazilian testing guidelines should be improved.

44

45 **Keywords:** Familial Breast Cancer, Genomics, Colorectal Neoplasms,
46 Population Genetics

47 **Introduction**

48 Hereditary cancer risk syndromes are a group of disorders caused by
49 germline pathogenic variants in a growing number of genes. They are the main
50 predisposing factor in about 5-10% of all diagnosed cancers. Accurate genetic
51 diagnosis in patients with hereditary cancer risk syndromes may reduce morbidity
52 and mortality by allowing the adoption of specific preventative and therapeutic
53 measures. Additionally, family members at risk can be tested and counseled,
54 extending the clinical benefits to many individuals ¹.

55 Currently, there are over 30 hereditary cancer syndromes already
56 described, the most prevalent being hereditary breast and ovarian cancer
57 syndrome (HBOC). Other syndromes include Li-Fraumeni, Cowden, Lynch,
58 Familial Adenomatous Polyposis (APC), multiple Endocrine Neoplasia Type 1 or
59 Wermer's Syndrome (MEN1), multiple Endocrine Neoplasia Syndrome - Type 2
60 (RET), and Von Hippel-Lindau Syndrome (VHL), to cite the most common. Most
61 syndromes are inherited in an autosomal-dominant manner, with variable
62 penetrance, and are caused by mutations in oncogenes or tumor suppressor
63 genes ². Although initially hard to diagnose genetically, the advent of next-
64 generation sequencing (NGS) has allowed for testing using panels with dozens
65 to hundreds of genes simultaneously and inexpensively ³. This has caused a
66 great increase in the clinical use of these NGS panels, while a growing body of
67 evidence show their clinical utility as compared to single-gene testing ^{4, 5}.

68 Although large studies have been published on the diagnostic utility of
69 such panels, these are mostly restricted to white populations. The aim of this
70 study was to describe the frequency and type of germline pathogenic variants in

71 cancer susceptibility genes in patients with clinical criteria of hereditary cancer
72 syndrome by NGS in the genetically admixed Brazilian population.

73 **Materials and methods**

74 **Inclusion and exclusion criteria**

75 The cohort to the retrospective study included 1682 Brazilian patients who
76 received a multi-gene NGS panel for risk of hereditary cancer in the Genomika
77 diagnostics unit, a genetics laboratory of the Albert Einstein Israeli Hospital
78 (Genomika-Einstein hereafter). As this study took place in a private diagnostic
79 laboratory this cohort was not specifically selected for any sex, age, ethnicity, or
80 history of cancer. Both patients with or without criteria for hereditary risk cancer
81 syndrome were considered. After genetic assessment we classified patients
82 according to the USA National Comprehensive Cancer Network (NCCN,
83 www.nccn.org) guidelines: genetic/familial high-risk assessment versions 3.2019
84 and 1.2020. Non-Brazilian patients were excluded.

85

86 **Research ethics statement**

87 This project was approved by the Institutional review board from the
88 Research Ethics Committee of the Institute of Integral Medicine Professor
89 Fernando Figueira (CEP-IMIP) in Recife, Pernambuco and all individuals
90 provided written consent for multi-gene testing (protocol number CAAE
91 29567220.4.1001.0071).

92

93 **Multigene genotyping panel**

94 Genotyping was performed through panels that covered the entire coding
95 region including 20 bp flanking each exon and noncanonical splice region.
96 Patients were sequenced with panels that ranged from 27 to 78 genes, including
97 genes mostly associated with hereditary cancer risk, such as *APC*, *ATM*, *BARD1*,
98 *BMPR1A*, *BRCA1*, *BRCA2*, *CDH1*, *CDK4*, *CHEK2*, *EGFR*, *EPCAM*, *GREM1*
99 *HOXB13*, *MEN1*, *MITF*, *MLH1*, *MRE11A*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*,
100 *PMS2*, *POLD1*, *POLE*, *PTEN*, *RAD50*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SMAD4*,
101 *STK11*, *TP53*, *VHL*. The complete list of genes is available in the Supplementary
102 Table 1).

103

104 **Library preparation for NGS**

105 Laboratory procedures were performed at Genomika-Einstein units
106 (Recife - PE and São Paulo - SP). Genomic DNA was extracted from peripheral
107 blood or saliva by automation (QIASymphony platform, QIAGEN, Hilden,
108 Germany) using the DNA Mini Kit extraction kit (QIAGEN). The quality and
109 quantity of the extracted DNA were assessed by fluorometry (Qubit, Thermo
110 Fisher, Waltham, Massachusetts). The genomic DNA was enzymatically
111 fragmented and enriched. The fragments were barcoded via multiplexed PCR
112 technology by QIAseq Targeted DNA Panels (CDHS 174272-2274 QIAGEN).
113 The genes were sequenced on MiSeq or Next-Seq 550 instruments (Illumina,
114 San Diego, CA) using MiSeq Reagent Kit v2 (300-cycles) or Next-Seq 550 High-
115 throughput kit (300 cycles) with 100% coverage and 50X minimum depth.

116

117 **Sanger sequencing**

118 In cases where variant confirmation was deemed necessary (low read
119 depth, complex indels), the genotype was determined by conventional PCR
120 followed by Sanger sequencing on an ABI 3500 (Thermo Fisher, Waltham,
121 Massachusetts) automatic sequencer. The variant call was made via the
122 reference transcript from the ATG initiation codon aligned against the GRCh37 /
123 hg19 reference genome.

124

125 ***Alu* insertion identification**

126 Relevant genetic screenings of breast/ovarian cancer families of
127 Portuguese ancestry demonstrate that the c.156_157ins*Alu* variant is the most
128 frequent *BRCA2* rearrangement. Detection of this variant was performed as
129 published elsewhere ⁶ . Briefly, PCR of *BRCA2* exon 3 was performed and the
130 *Alu* insertion is detected by differential agarose gel electrophoresis.

131

132 **Variant classification and bioinformatic analysis**

133 Bioinformatic analysis was performed using GATK 3.0 best practices.
134 VCFs were annotated using Annovar and in-house databases. The clinical
135 significance of the variants was determined according to the criteria of the
136 American College of Genomics and Genetics (ACMG) 2015 guidelines for
137 sequence variant interpretation and 2018 guideline update ^{7, 8}. Each variant
138 classification were performed independently by two specialists. Allelic frequency
139 was examined through access to population databases as Genome Aggregation
140 Database (gnomAD) ⁹, Exome Aggregation Consortium (ExAC) ¹⁰, and The 1000

141 Genomes Project ¹¹. Disease information were upload form ClinVar ¹² and the
142 Leinden Open Variation Database (LOVD) ¹³. All variant information used for
143 classification were updated and upgraded in an in-house local knowledgebase.

144 **Results**

145 **Study sample characteristics and cancer histories**

146 Between July 2016 and July 2019, we collected samples and
147 clinical/demographic characteristics from 1682 Brazilian individuals referred to a
148 private laboratory to undergo genotyping with a cancer hereditary risk multigenic
149 panel (Table 1).

150 Among the individuals, 1557 (92.6%) were women with mean age of 47.4
151 \pm 12.3 (range 11-88) years and 125 (7.4%) were men with mean age of 51.4 \pm
152 15.2 (range 14-91) years. Regarding ethnic ancestry, 1007 (59.9%) individuals
153 reported unknown background, 330 (19.6%) reported having multiple ethnicities
154 (admixed), 259 (15.4%) white, 26 (1.5%) black, 22 (1.3%) Ashkenazi Jewish, 21
155 (1.2%) native indigenous and 17 Asian (1.0%) (Table 1).

156 Personal cancer history was reported by 1126 (66.9%) individuals, with
157 breast or ovary cancers identified in 971 individuals (57.7%); colorectal cancer in
158 71 (4.2%); thyroid/parathyroid in 36 (2.1%); prostate cancer in 15 (0.9%);
159 stomach cancer in 14 (0.8%); uterus, kidney, and sarcomas in 13 each (0.8%);
160 leukemia in 11 (0.6%); non-melanoma skin and pancreas cancers in 9 each
161 (0.5%); and melanoma in 6 (0.4%). Other types of cancer (lung, liver, bladder,
162 larynx etc.) were identified in 17 individuals (1.0%). Overall, 268 individuals
163 (15.9%) did not present malignant neoplasms and for 293 individuals (17.4%) the
164 history information was not available.

165 Family cancer history (considering first-, second- or third-degree relatives)
166 was reported by 1182 (70.3%) individuals: 806 (47.9%) reported breast cancer
167 family history; 310 (23.0%) colorectal cancers; 339 (20.2%) prostate cancer; 219
168 (13.0%) head and neck tumors; 172 (10.2%) lung cancer; 155 (9.2%) stomach
169 cancer; 119 (7.1%) breast and ovarian and 48 (2.9%) ovarian cancer exclusively.
170 No family history was reported by 163 (9.7%) individuals and 337 (20.0%) did not
171 provide information regarding family history (Table 1, Supplementary Table 2).

172

173 Genetic findings

174 Pathogenic or likely pathogenic variants were found in 305 (18.1%) of the
175 1682 individuals. Additionally, 1252 variants of uncertain significance (VUS) were
176 found in 753 (44.8%) individuals (Figure 1A, Supplementary Table 3). The
177 remaining 624 (37.1%) patients did not present any variants of clinical interest
178 whatsoever (negatives).

179 The 305 individuals collectively had 321 pathogenic/likely pathogenic
180 variant hits (corresponding to 166 unique variants) in 32 genes: *APC*, *ATM*,
181 *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CDK4*, *CHEK2*, *EPCAM*, *FANCC*,
182 *MEN1*, *MITF*, *MLH1*, *MRE11A*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PMS2*,
183 *POLD1*, *PTCH2*, *PTEN*, *RAD50*, *RAD51*, *RAD51C*, *RAD51D*, *RB1*, *RECQL*, *RET*
184 and *TP53*.

185 The genes that most commonly presented pathogenic or likely pathogenic
186 variants were *BRCA1* (84/321 = 26.2%), *BRCA2* (46, 14.3%) and *PALB2* (25,
187 7.8%). Lynch syndrome genes (*MLH1*, *MSH2*, *MSH6* and *PMS2*) came next with
188 17 (5.3%) and were tied with *TP53*, also with 17 (5.3%) hits. Next came *ATM* (15,
189 4.7%), *CHEK2* (14, 4.4%), *RAD51C* (9, 2.8%), *RAD51* (8, 2.5%), *RAD50* (7,

190 2.2%), *BRIP1* (6, 1.9%), *BARD1* (4, 1.2%), *PTEN* (4, 1.2%), *RAD51D* (4, 1.2%),
191 and *APC* (3, 0.9%). Other genes amounted 17 (3.0%) variants (*NBN*, *RET*,
192 biallelic *MUTYH*, *MITF*, *CDH1*, *EPCAM*, *FANCC*, *MRE11*, *POLD1*, *RB1*, *RECQL*,
193 *MEN1*, *CDK4* and *PTCH2*). Moreover, monoallelic *MUTYH* variants, considered
194 to have low penetrance, were detected in 42 (13.1%) cases (Figure 1B).

195 In terms of unique variants, we detected 24 in *BRCA1*, 32 in *BRCA2*, 16 in
196 *PALB2*, 16 in the Lynch syndrome genes, eight in *TP53*, 14 in *ATM*, eight in
197 *CHEK2*, six in *RAD51C*, nine in *RAD51*, two in *RAD50*, six in *BRIP1*, four in
198 *PTEN*, two in *RAD51*, three in *APC*, two in *NBN*, eight in *MUTYH*, two in *CDH1*
199 and one each in *BARD1*, *RET*, *MITF*, *EPCAM*, *FANCC*, *MRE11*, *POLD1*, *RB1*,
200 *RECQL*, *MEN1*, *CDK4* and *PTCH2*.

201 Among the 321 pathogenic/likely pathogenic variant hits, 84 (26.2%) were
202 point mutations in conserved splice sites, 73 (22.7%) were frameshift deletions,
203 65 (20.2%) were missense point mutations, 58 (18.1%) were nonsense point
204 mutations, 22 (6.9%) were frameshift duplications, 10 (3.1%) were frameshift
205 insertions, four (1.3%) were frameshift indels, four inframe deletions (1.3%), and
206 a single inframe insertion (0.3%) (Figure 1C).

207 Most of the 1252 VUS hits (corresponding to 886 unique variants) were
208 identified in *ATM* (198 hits, 15.8%), followed by *BRCA2* (86, 6.9%), *MHS6* (63,
209 5.0%), *BRIP1* (55, 4.4%), *RAD50* (52, 4.2%), *CHEK2* (38, 3.0%), *PALB2* (34,
210 2.7%), *MHS2* (31, 2.5%), *MLH1* (17, 1.4%), *TP53* (17, 1.4%), *BRCA1* (17, 1.4%).
211 Other genes amounted to 644 (51.4%) VUS (Figure 1D).

212

213 **Individuals with multiple variants (transheterozygotes)**

214 Among the 305 individuals with pathogenic/likely pathogenic variants, 290
215 (95.1%) were single heterozygotes, 14 (4.6%) presented two variants in different
216 genes (any two of these: *APC*, *ATM*, *BRCA1*, *BRCA2*, *CDK4*, *CHEK2*, *MEN1*,
217 *MUTYH*, *PALB2*, *PMS2*, *RAD51*, *RAD51C* or *TP53*) and a single patient (0.3%)
218 presented three pathogenic variants in different genes (*BRCA1*, *MSH6* and
219 *MUTYH*). The most common combination in the patients with two variants was a
220 variant in a high-penetrance gene, such as *BRCA1* and *BRCA2*, alongside a
221 variant with lower penetrance, such as monoallelic *MUTYH* or in *CHEK2*. No
222 patients presented more than one pathogenic/likely pathogenic variants in the
223 same gene (Figure 2, Supplementary Table 4). We observed a single individual
224 *BRCA1/BRCA2* double heterozygote, making the double heterozygotes
225 prevalence among *BRCA* variants carriers about 0.78% (1/129) and 0.06%
226 (1/1682) overall. Thus, the overall transheterozygosity prevalence was about
227 0.89% (15/1682) in our sample.

228

229 **Positivity profiles according to testing criteria of the USA National** 230 **Comprehensive Cancer Network and Brazilian National Health Agency**

231 The sampled individuals were assessed for hereditary cancer testing
232 indication according to two sets of clinical criteria: the NCCN for hereditary
233 breast/ovarian, colorectal, stomach or pancreas cancer syndromes, version
234 3.2019 and 1.2020 and the criteria of the Brazilian National Health Agency (ANS).

235 Among the 1682 individuals in study, 1008 (59.9%) met NCCN 3.2019 and
236 1.2020 criteria for testing, 368 (21.9%) did not meet the criteria and 306 did not
237 have sufficient information for classification. Forty-five patients among the 305

238 that presented pathogenic/likely pathogenic (positive patients) were in the last
239 group, leaving 260 classifiable patients. The true positive rate of NCCN criteria
240 was 215/260 (82.7%) and the false negative rate was 45/260 (17.3%). The F1-
241 measure was 33.9%. Regarding ANS criteria, 660 (39.2%) met the criteria for
242 testing, 691 did not meet and 331 did not have sufficient information for
243 classification. The true positive rate of ANS was 145/260 (55.7%) and the false
244 negative rate was 115/260 (44.2%), and F1-measure was 31.5% (Table 2).

245 The group of 215 patients fulfilling testing criteria according to the NCCN
246 had the following genetic profiles: 72 (36.4%) individuals having variants in
247 *BRCA1*, 29 (14.6%) in *BRCA2*, 16 (8.1%) in *PALB2*, 14 (7.1%) in *TP53*, 11
248 (5.6%) in *ATM*, 9 (4.5%) in *CHEK2*, 7 (3.5%) in *RAD50* and *RAD51*, 6 (3.5%) in
249 *RAD51C*, 4 (2.0%) in *MSH6*, 3 (1.5%) in *BRIP1*, *MSH2* and *RAD51D*, 2 (1.0%)
250 in *APC*, *BARD1* and *CDH1* e 8 (4.0%) in other genes (*MEN1*, *MITF*, *MLH1*, *NBN*,
251 *PMS2*, *POLD1*, *PTEN* and *RECQL*).

252 The group of 45 patients who did not meet the NCCN criteria had the
253 following profiles: 9 (20.0%) individuals with variants in *MUTYH*, 7 (16.7%) in
254 *BRCA2*, 6 (14.3%) in *BRCA1*, 5 (11.9%) in *PALB2*, 2 (4.8%) in *ATM*, *CHEK2*,
255 *MLH1*, *MSH6*, *PTEN*, *RET* and *TP53*, besides 10 (23.8%) in other genes
256 (*BARD1*, *BRIP1*, *CDK4*, *FANCC*, *MRE11A*, *MSH2*, *PMS2*, *PTCH2*, *RAD51* and
257 *RAD51C*).

258 In summary, both NCCN 1.2020/3.2019 and ANS criteria failed to detect a
259 substantial part of positive patients. The Brazilian criteria fared even worse,
260 missing about 44% of positive patients, versus approximately 17% with NCCN
261 1.2020/3.2019.

262

263 **Geographic distribution of variants**

264 We stratified our data according to each Brazilian state. The results are
265 available in the Supplementary Table 5.

266 **Discussion**

267 Cancers were the second most common cause of death worldwide in
268 2018, with 9.6 million deaths (1 every 6 deaths). Lung, prostate, colorectal,
269 stomach and liver are the most common in men, whereas women are more
270 affected by breast, colorectal, lung, cervix and thyroid ¹⁴. The Brazilian National
271 Cancer Institute (INCA) estimates 450,000 new cancer cases per year (excluding
272 non-melanoma skin cancers) for the 2020-2022 triennium ¹⁵.

273 Most tumors are sporadic, caused by somatic genetic events. However,
274 about 10% of the patients carry germline pathogenic variants in cancer
275 predisposition genes such as *BRCA1* or *BRCA2* ¹. The identification of these
276 patients is of utmost clinical importance because early diagnosis of hereditary
277 cancer risk syndromes may improve vigilance and treatment. Therefore, genetic
278 investigation is already a tool of modern oncology ¹⁶.

279 Next generation sequencing (NGS) technologies reduced sequencing
280 costs allowing rapid, precise, and simultaneous analysis of a great quantity of
281 genetic material. NGS has been used to identify genetic causes of rare diseases
282 and cancers, in clinical and research settings. Previously, patients in investigation
283 of HBOC or Lynch syndrome risk would be genotyped by limited, specific panels.
284 Nowadays, as NGS is being largely utilized by clinical laboratories, the patients
285 may undergo genotyping by multigenic panels that allow a better stratification as
286 well as personalized oncologic management ¹⁷.

287 Here, we report the results of our study, the largest conducted in Brazil,
288 with 1682 individuals that underwent genotyping with 27- to 78-genes panels
289 intended to detect germinative variants in cancer predisposition genes. Women
290 are the majority in our sample (92.6%). Consequently, the most prevalent cancers
291 were breast and ovarian (57.7%), colorectal (4.2%) and thyroid/parathyroid
292 (2.1%).

293 The overall positivity rate was 18.1% (305/1682 individuals); 16.0%
294 (269/1682) if individuals with monoallelic *MUTYH* variants are excluded.
295 Considering just *BRCA1/BRCA2* pathogenic/likely pathogenic variants, the
296 positivity rate was only 7.7% (129/1682 individuals). This demonstrates the
297 importance of NGS multigene panels: it reduces the rate of false negatives,
298 providing more information for oncologic management and prognosis.

299 The *BRCA* pathogenic variants positivity rate from our study seems low,
300 but it is not unexpected since our cohort was not specifically selected for any sex,
301 age, ethnicity, or history of cancer. Indeed, since there is significant allelic
302 heterogeneity in *BRCA* genes, there is great variability in positivity rates in other
303 studies¹⁸. In Brazil, studies of HBOC patients observed positivity rates between
304 1.3%¹⁹ and 27.3%²⁰. In other countries, the positivity rate among sporadic and
305 high-risk hereditary cancer cases varied between 2.6% in the USA²¹ and 27.9%
306 in Japan²² (reviewed in²³). Therefore, our positivity rate is indeed within these
307 ranges.

308 We compared the mutational profile of *BRCA1* and *BRCA2* genes we
309 observed with other 20 Brazilian studies. Among the 56 variants we detected, 33
310 (19 in *BRCA1* and 14 in *BRCA2*) were recurrent in other studies. The five most
311 recurrent variants were: *BRCA1*:c.5266dupC, found by other 18 studies^{18, 20, 24-}

312 ³⁹, *BRCA1*:c.3331_3334delCAAG, found in other 12 studies ^{18, 20, 24, 27, 29, 31, 32, 34,}
313 ^{35, 37, 39, 40}, *BRCA2*:c.2808_2811delACAA found in other seven studies ^{18, 29-31, 34,}
314 ^{35, 39}, *BRCA1*: c.1687C>T found in six studies ^{26, 31, 32, 34, 35} and *BRCA1*:c.211A>G
315 found in other five studies ^{35-38, 40}.

316 The five most prevalent *BRCA1* mutations among the individuals sampled
317 by our study were c.5266dupC, c.5074+2T>C, c.3331_3334delCAAG,
318 c.1687C>T and c.211A>G. These results partially agree with a worldwide survey
319 that included Brazilian families of women carriers of *BRCA* pathogenic variants.
320 Rebbeck et al. (2018) ⁴¹ surveyed 101 Brazilian families and observed
321 c.5266dupC, c.3331_3334delCAAG and c.1687C>T among the five most
322 prevalent *BRCA1* mutations. Therefore, our results agree with three variants.

323 The five most prevalent *BRCA2* variants in our patients were
324 c.2808_2811delACAA, c.9382C>T, c.6024dupG, c.8488-1G>A and c.5216dupA.
325 Only c.2808_2811delACAA was in common with the Rebbeck et al. results ⁴¹.
326 Interestingly, they observed c.156_157insAlu among the five most prevalent
327 variation among 49 Brazilian families, but our results place it in sixth place, tied
328 with other variants.

329 The recurrence in independent samples from Brazil indicate the variants
330 are representative of the *BRCA1* and *BRCA2* mutational spectrum in Brazil.
331 Indeed, the *BRCA1*:c.5266dupC and *BRCA2*:c.156_157insAlu (found in other
332 four studies ^{31, 34, 35, 42}) variants are considered as founder mutations coming from
333 European populations and may be found in the individuals from all regions of
334 Brazil ³⁵. Indeed, we detected *BRCA1*: c.5266dupC in individuals from
335 Pernambuco and Alagoas, Northeast Brazil states, as well as in São Paulo

336 (Southeast) and Paraná (South) and *BRCA2*:c.156_157insAlu was detected in
337 an individual from Piauí, also a Northeast state.

338 We also observed some recurrent pathogenic variants in other genes:
339 *TP53*:c.1010G>A, found in four other studies^{20, 38-40}, *CHEK2*:c.349A>G, found in
340 two other studies^{38, 43}; *MUTYH*:c.1147delC⁴³; *MUTYH*:c.1187G>A³⁸,
341 *MSH2*:c.2152C>T⁴⁴; *MSH6*:c.3848_3862del⁴⁵, *MLH1*:c.677G>A⁴⁴ and
342 *PALB2*:c.2257C>T⁴⁶. These observations could mean that these variants are
343 important co-players alongside the recurrent *BRCA* variants in the risk of
344 hereditary cancers in Brazilian populations.

345 Transheterozygosity, i.e. heterozygosity at two different loci⁴⁷, is rare
346 among patients at risk of hereditary cancers. The prevalence of double
347 heterozygosity among *BRCA1/BRCA2* carriers ranges between 1.8% and 1.85%
348^{48, 49} in the Jewish Ashkenazi populations. Among non-Ashkenazi Europeans, the
349 prevalence is lower, between 0.22% and 0.87%⁴⁸. An Italian study reported
350 0.62%⁵⁰ and a Korean study reported 1.2%⁵¹. Therefore, our estimate of 0.78%
351 in the Brazilian sample seems plausible.

352 There has been controversy regarding the consequences over the
353 phenotype of *BRCA1/BRCA2* double heterozygote. Earlier reports suggest that
354 they do not have worse phenotypes when comparing to single-variant carriers⁵²,
355⁵³. Bell et al. (2002)⁵⁴ analyzed three independent samples of tumor tissue from
356 the same *BRCA1/BRCA2* double heterozygote patient and observed that either
357 one or other gene had suffered loss of heterozygosity (LOH) genetic events,
358 suggesting that both genes are functionally equivalent in initiating tumorigenesis
359 in breast tissue. Therefore, double heterozygote status would be equivalent to
360 single-carrier status. Other case reports, case series and review of case reports

361 also suggested that double heterozygote status was not associated with more
362 severe phenotype ^{48, 55, 56}. In contrast, Randall et al. (1998) ⁵⁷ observed LOH in
363 both genes in ovarian tumors, perhaps signaling that the pathogenic events in
364 each tissue are different and not always *BRCA1* mutations are equivalent to
365 *BRCA2* counterparts.

366 However, more recent large surveys have been suggesting that double
367 heterozygote have different phenotypes when compared to single heterozygote
368 individuals. A large survey of 8162 German families with breast/ovarian cancer
369 cases found eight double heterozygote individuals. They observed that they were
370 younger at the onset of their first cancer episode when compared with their single
371 heterozygote relatives and had more severe disease ⁵⁸. A worldwide survey of
372 32,295 women compared the clinical history of double heterozygote individuals
373 with breast cancer to their single heterozygote counterparts. The same was done
374 for ovarian cancer cases. They observed that clinical characteristics of double
375 heterozygote individuals resemble phenotypes from *BRCA1*-only single
376 heterozygotes, but tumor LOH microsatellite markers patterns are intermediate
377 to the patterns of *BRCA1*-only single heterozygote and *BRCA2*-only single
378 heterozygote. Thus, the authors suggest that the joint effect of *BRCA1/BRCA2*
379 variants are compatible with an additive model ⁴⁷. Another recent study also
380 suggests that the double heterozygote phenotype more closely resembled that of
381 *BRCA1* mutation carriers with poor prognosis factors and proposed a co-
382 dominant model for the joint effects ⁵⁹.

383 In summary, *BRCA1/BRCA2* double heterozygote may have early onset
384 of disease and the phenotype is perhaps similar to the “severe end of spectrum
385 of *BRCA1* mutation carriership” ⁴⁸. We found a single *BRCA1/BRCA2* double

386 heterozygote woman in our sample. She presented personal history of breast
387 cancer. Since she is in her late 40s, her first cancer case must have happened
388 much earlier, however, detailed data on her phenotype is currently lacking.

389 Literature on *BRCA*/other genes double heterozygotes is sparser. Thus,
390 comparison with our results was difficult due to the possible different
391 combinations of variants. For example, Sokolenko et al. (2014) ⁶⁰ found seven
392 digenic combinations double heterozygotes among *BRCA1* and other DNA
393 double-strand repair genes (*BRCA1/CHEK2*, *BRCA1/ATM*, *BRCA1/BLM*,
394 *CHEK2/BLM*, *CHEK2/ATM*, *NBS1/ATM*, and *NBS1/BLM*) in Russian patients:
395 none were observed in our study. They did not observe differences from single
396 heterozygote individuals. In contrast, a case series including a German
397 *BRCA1/PALB2* double heterozygous patient had no early onset but had severe
398 disease (multifocal triple negative ductal carcinoma) ⁶¹. Another case report
399 presented a case of a double heterozygote *APC/MLH1* man with
400 Kashmir/Egyptian ancestry, which had a history of six jejunal cancers ⁶².
401 Therefore, double heterozygosity may have unusual effects on cancer
402 phenotypes. However, we did not find *APC/MLH1* double heterozygous, but
403 found an individual *APC/TP53* double heterozygote, so it is another case
404 warranting further investigation.

405 Perhaps the joint effects of non-*BRCA* variants can be explained in an
406 additive manner as well. Thus, some combinations will result in severe
407 phenotypes while others will not, due to the specific penetrance of each variant.
408 It seems that non-*BRCA* double heterozygotes will need to be analyzed on a
409 case-by-case basis.

410 We found that NCCN 1.2020 criteria missed a substantial proportion of
411 patients that had pathogenic/likely pathogenic variants. Other authors observed
412 the same. We found that NCCN criteria missed a substantial proportion of
413 patients that had pathogenic/likely pathogenic variants. Other authors observed
414 the same. For example, Grindedal et al. (2017)⁶³ investigated *BRCA* mutations
415 in a Norwegian breast cancer cohort and assessed some testing criteria,
416 including NCCN, and found a false negative rate of 15.8%. Yang et al. (2018)⁶⁴
417 investigated 4196 patients genotyped with 40- to 80- genes panels and showed
418 a false negative rate of 13.5% with NCCN criteria. Both were not much far from
419 our estimate of 17% with NCCN 1.2020/3.2019.

420 Other authors proposed changes to NCCN criteria. Alemar et al. (2017)³⁴
421 found that adding criteria that are not included in the NCCN and ANS criteria (e.g.
422 some ASCO criteria^{65, 66}) achieved a higher predictive value, while other authors
423 compared other four algorithms (BOADICEA^{67, 68}, BRCAPRO, Myriad⁶⁹ and
424 Manchester score⁷⁰) and observed that the pedigree-based BOADICEA most
425 accurately predicted *BRCA1/BRCA2* variant carrier status in a Southeastern
426 Brazilian population⁷¹. Although NCCN criteria were imperfect, ANS criteria fared
427 worse and a reformulation is warranted.

428 Recently, a panel of Brazilian experts proposed recommendations for
429 improving testing criteria for HBOC risk patients in Brazil. Besides modifying
430 testing criteria, the expert panel also recommended offering risk-reducing
431 surgeries for positive patients. For negative patients, investigating both maternal
432 and paternal lineages is warranted, so the result of models estimating cancer risk
433 can be communicated to the patient. They also suggested that VUS should
434 always be reported and periodically reassessed, but no urgent clinical action is

435 justified since most VUS are constantly reclassified to benign/likely benign
436 categories. Furthermore, patients should be contacted whenever any update in
437 testing protocols or management options should appear ⁷².

438 Our study had some limitations. The NGS panel detects small deletions
439 and duplications up to 17 base-pairs, but large deletions and duplications are not
440 detected by this methodology. Other structural chromosomal changes, such as
441 inversions and translocations are not detected either. If some of these changes
442 are suspected, we recommend using methodologies like array CGH, MLPA,
443 qPCR or FISH to confirm the variant found. Expansion variants of trinucleotide
444 repeats, deep intronic variants or regulatory regions such as promoters are not
445 detectable in the present test. Epigenetic changes are also not detectable by this
446 test. At least for *BRCA* genes though, large rearrangements seem to be
447 uncommon in Brazilian populations ^{35, 42}. Moreover, further phenotype
448 information was missing for several patients, precluding further analyses.

449 **Conclusion**

450 In conclusion, we genotyped 1682 Brazilian individuals with clinical criteria
451 of hereditary cancer syndrome from all regions of the country with NGS multigenic
452 panels suited for the detection of germline pathogenic variants associated with
453 cancer susceptibility, making it the largest Brazilian study of this nature to date.
454 We observed several *BRCA1* and *BRCA2* recurrent mutations, confirming their
455 presence in the Brazilian mutational spectrum and generated data for other 30
456 genes and 110 variants with modest penetrance. We also estimated the
457 prevalence of *BRCA* as well as non-*BRCA* double heterozygotes in the Brazilian

458 population. More studies are necessary to discover the implication of
459 transheterozygosity over the phenotype of affected individuals.

460 **References**

- 461 1. Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
462 Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1:
463 Breast-Ovarian Cancer Syndromes. *Mayo Clin Proc*. Jun 2019;94(6):1084-1098.
464 doi:10.1016/j.mayocp.2019.02.017
- 465 2. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes.
466 *Oncogene*. 2004;23(38):6445-6470. doi:10.1038/sj.onc.1207714
- 467 3. Zelli V, Compagnoni C, Cannita K, et al. Applications of Next Generation
468 Sequencing to the Analysis of Familial Breast/Ovarian Cancer. *High Throughput*.
469 Jan 10 2020;9(1)doi:10.3390/ht9010001
- 470 4. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the
471 clinic: Promises and challenges. *Cancer Letters*. 2013;340(2):284-295.
472 doi:10.1016/j.canlet.2012.11.025
- 473 5. Yohe S, Thyagarajan B. Review of Clinical Next-Generation Sequencing.
474 *Archives of Pathology & Laboratory Medicine*. 2017;141(11):1544-1557.
475 doi:10.5858/arpa.2016-0501-ra
- 476 6. Machado PM, Brandao RD, Cavaco BM, et al. Screening for a BRCA2
477 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder
478 effect and analysis of the associated phenotypes. *J Clin Oncol*. May 20
479 2007;25(15):2027-34. doi:10.1200/JCO.2006.06.9443
- 480 7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
481 interpretation of sequence variants: a joint consensus recommendation of the
482 American College of Medical Genetics and Genomics and the Association for
483 Molecular Pathology. *Genet Med*. May 2015;17(5):405-24.
484 doi:10.1038/gim.2015.30
- 485 8. Biesecker LG, Harrison SM, ClinGen Sequence Variant Interpretation
486 Working G. The ACMG/AMP reputable source criteria for the interpretation of
487 sequence variants. *Genet Med*. Dec 2018;20(12):1687-1688.
488 doi:10.1038/gim.2018.42
- 489 9. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint
490 spectrum quantified from variation in 141,456 humans. *Nature*. 2020/05/01
491 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 492 10. Karczewski KJ, Weisburd B, Thomas B, et al. The ExAC browser:
493 displaying reference data information from over 60 000 exomes. *Nucleic Acids
494 Research*. 2017;45(D1):D840-D845. doi:10.1093/nar/gkw971
- 495 11. The 1000 Genomes Project Consortium. A global reference for human
496 genetic variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393
- 497 12. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to
498 variant interpretations and supporting evidence. *Nucleic Acids Research*.
499 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153
- 500 13. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, Den
501 Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. *Human
502 Mutation*. 2011;32(5):557-563. doi:10.1002/humu.21438

- 503 14. Organization WH. WHO report on cancer: setting priorities, investing
504 wisely and providing care for all. 2020.
- 505 15. Instituto Nacional de Câncer José Alencar Gomes da Silva. Ministério da
506 Saúde. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: Instituto
507 Nacional de Câncer José Alencar Gomes da Silva; 2019. p. 120.
- 508 16. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its
509 molecular characteristics, screening, treatment, and prognosis. *Breast Cancer*.
510 Aug 29 2020;doi:10.1007/s12282-020-01148-2
- 511 17. Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing
512 Personalized Medicine Through the Application of Whole Exome Sequencing and
513 Big Data Analytics. *Front Genet*. 2019;10:49. doi:10.3389/fgene.2019.00049
- 514 18. Alemar B, Herzog J, Brinckmann Oliveira Netto C, et al. Prevalence of
515 Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian
516 cancer patients from Brazil reveals differences among Latin American
517 populations. *Cancer Genet*. Sep 2016;209(9):417-422.
518 doi:10.1016/j.cancergen.2016.06.008
- 519 19. Dillenburger CV, Bandeira IC, Tubino TV, et al. Prevalence of 185delAG and
520 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi
521 Jewish origin in southern Brazil. *Genet Mol Biol*. Jul 2012;35(3):599-602.
522 doi:10.1590/S1415-47572012000400009
- 523 20. Cipriano NM, Jr., de Brito AM, de Oliveira ES, et al. Mutation screening of
524 TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and
525 ovarian cancer (HBOC) in Brazil. *Breast Cancer*. May 2019;26(3):397-405.
526 doi:10.1007/s12282-018-00938-z
- 527 21. Susswein LR, Marshall ML, Nusbaum R, et al. Pathogenic and likely
528 pathogenic variant prevalence among the first 10,000 patients referred for next-
529 generation cancer panel testing. *Genet Med*. Aug 2016;18(8):823-32.
530 doi:10.1038/gim.2015.166
- 531 22. Sugano K, Nakamura S, Ando J, et al. Cross-sectional analysis of germline
532 BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary
533 breast/ovarian cancer. *Cancer Sci*. Oct 2008;99(10):1967-76.
534 doi:10.1111/j.1349-7006.2008.00944.x
- 535 23. Okano M, Nomizu T, Tachibana K, et al. The relationship between BRCA-
536 associated breast cancer and age factors: an analysis of the Japanese HBOC
537 consortium database. *J Hum Genet*. Mar 2021;66(3):307-314.
538 doi:10.1038/s10038-020-00849-y
- 539 24. Lourenço JJ, Vargas FR, Bines J, et al. BRCA1 mutations in Brazilian
540 patients. *Genetics and Molecular Biology*. 2004;27:500-504.
- 541 25. Dufloth RM, Carvalho S, Heinrich JK, et al. Analysis of BRCA1 and BRCA2
542 mutations in Brazilian breast cancer patients with positive family history. *Sao
543 Paulo Med J*. Jul 7 2005;123(4):192-7. doi:10.1590/s1516-31802005000400007
- 544 26. Gomes MC, Costa MM, Borojevic R, et al. Prevalence of BRCA1 and
545 BRCA2 mutations in breast cancer patients from Brazil. *Breast Cancer Res Treat*.
546 Jul 2007;103(3):349-53. doi:10.1007/s10549-006-9378-6
- 547 27. Esteves VF, Thuler LC, Amendola LC, et al. Prevalence of BRCA1 and
548 BRCA2 gene mutations in families with medium and high risk of breast and
549 ovarian cancer in Brazil. *Braz J Med Biol Res*. May 2009;42(5):453-7.
550 doi:10.1590/s0100-879x2009000500009
- 551 28. Ewald IP, Izetti P, Vargas FR, et al. Prevalence of the BRCA1 founder
552 mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and

- 553 ovarian cancer syndrome. *Hered Cancer Clin Pract.* Dec 20 2011;9(1):12.
554 doi:10.1186/1897-4287-9-12
- 555 29. Carraro DM, Koike Folgueira MA, Garcia Lisboa BC, et al. Comprehensive
556 analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor
557 characterization: a portrait of early-onset breast cancer in Brazil. *PLoS One.*
558 2013;8(3):e57581. doi:10.1371/journal.pone.0057581
- 559 30. Silva FC, Lisboa BC, Figueiredo MC, et al. Hereditary breast and ovarian
560 cancer: assessment of point mutations and copy number variations in Brazilian
561 patients. *BMC Med Genet.* May 15 2014;15:55. doi:10.1186/1471-2350-15-55
- 562 31. Fernandes GC, Michelli RA, Galvão HC, et al. Prevalence of
563 BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary
564 breast cancer and characterization of its genetic ancestry. *Oncotarget.* Dec 6
565 2016;7(49):80465-80481. doi:10.18632/oncotarget.12610
- 566 32. Maistro S, Teixeira N, Encinas G, et al. Germline mutations in BRCA1 and
567 BRCA2 in epithelial ovarian cancer patients in Brazil. *BMC cancer.* Dec 3
568 2016;16(1):934. doi:10.1186/s12885-016-2966-x
- 569 33. de Oliveira ES, Soares BL, Lemos S, et al. Screening of the BRCA1 gene
570 in Brazilian patients with breast and/or ovarian cancer via high-resolution melting
571 reaction analysis. Article. *Fam Cancer.* Apr 2016;15(2):173-181.
572 doi:10.1007/s10689-015-9858-0
- 573 34. Alemar B, Gregório C, Herzog J, et al. BRCA1 and BRCA2 mutational
574 profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands
575 from Southern Brazil: Are international testing criteria appropriate for this specific
576 population? *PLOS ONE.* 2017;12(11):e0187630.
577 doi:10.1371/journal.pone.0187630
- 578 35. Palmero EI, Carraro DM, Alemar B, et al. The germline mutational
579 landscape of BRCA1 and BRCA2 in Brazil. *Sci Rep.* Jun 15 2018;8(1):9188.
580 doi:10.1038/s41598-018-27315-2
- 581 36. Brianese RC, Nakamura KDM, Almeida F, et al. BRCA1 deficiency is a
582 recurrent event in early-onset triple-negative breast cancer: a comprehensive
583 analysis of germline mutations and somatic promoter methylation. *Breast Cancer*
584 *Res Treat.* Feb 2018;167(3):803-814. doi:10.1007/s10549-017-4552-6
- 585 37. Cotrim DP, Ribeiro ARG, Paixão D, et al. Prevalence of BRCA1 and
586 BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian
587 carcinoma patients in Brazil. *BMC cancer.* Jan 3 2019;19(1):4.
588 doi:10.1186/s12885-018-5235-3
- 589 38. Bandeira G, Rocha K, Lazar M, et al. Germline variants of Brazilian women
590 with breast cancer and detection of a novel pathogenic ATM deletion in early-
591 onset breast cancer. *Breast Cancer.* Sep 28 2020;doi:10.1007/s12282-020-
592 01165-1
- 593 39. Da Costa E Silva Carvalho S, Cury NM, Brotto DB, et al. Germline variants
594 in DNA repair genes associated with hereditary breast and ovarian cancer
595 syndrome: analysis of a 21 gene panel in the Brazilian population. *BMC Medical*
596 *Genomics.* 2020;13(1)doi:10.1186/s12920-019-0652-y
- 597 40. Felix GE, Abe-Sandes C, Machado-Lopes TM, et al. Germline mutations
598 in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC:
599 characterizing a Northeast Brazilian Population. *Hum Genome Var.*
600 2014;1:14012. doi:10.1038/hgv.2014.12

- 601 41. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a
602 worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat.*
603 May 2018;39(5):593-620. doi:10.1002/humu.23406
- 604 42. Ewald IP, Cossio SL, Palmero EI, et al. BRCA1 and BRCA2
605 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian
606 Cancer Syndrome. *Genet Mol Biol.* Apr-Jun 2016;39(2):223-31.
607 doi:10.1590/1678-4685-gmb-2014-0350
- 608 43. Felicio PS, Grasel RS, Campacci N, et al. Whole-exome sequencing of
609 non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary
610 breast/ovarian cancer. *Hum Mutat.* Dec 16 2020;doi:10.1002/humu.24158
- 611 44. Soares BL, Brant AC, Gomes R, et al. Screening for germline mutations in
612 mismatch repair genes in patients with Lynch syndrome by next generation
613 sequencing. *Fam Cancer.* Jul 2018;17(3):387-394. doi:10.1007/s10689-017-
614 0043-5
- 615 45. Rosa RCA, Santis JO, Teixeira LA, et al. Lynch syndrome identification in
616 a Brazilian cohort of endometrial cancer screened by a universal approach.
617 *Gynecol Oncol.* Oct 2020;159(1):229-238. doi:10.1016/j.ygyno.2020.07.013
- 618 46. Gomes R, Spinola PDS, Brant AC, et al. Prevalence of germline variants
619 in consensus moderate-to-high-risk predisposition genes to hereditary breast and
620 ovarian cancer in BRCA1/2-negative Brazilian patients. *Breast Cancer Res Treat.*
621 Oct 30 2020;doi:10.1007/s10549-020-05985-9
- 622 47. Rebbeck TR, Friebel TM, Mitra N, et al. Inheritance of deleterious
623 mutations at both BRCA1 and BRCA2 in an international sample of 32,295
624 women. *Breast Cancer Research.* Nov 11 2016;18112. doi:10.1186/s13058-016-
625 0768-3
- 626 48. Leegte B, van der Hout AH, Deffenbaugh AM, et al. Phenotypic expression
627 of double heterozygosity for BRCA1 and BRCA2 germline mutations. *J Med*
628 *Genet.* Mar 2005;42(3):e20. doi:10.1136/jmg.2004.027243
- 629 49. Lavie O, Narod S, Lejbkowitz F, et al. Double heterozygosity in the BRCA1
630 and BRCA2 genes in the Jewish population. *Ann Oncol.* Apr 2011;22(4):964-966.
631 doi:10.1093/annonc/mdq460
- 632 50. Zuradelli M, Peissel B, Manoukian S, et al. Four new cases of double
633 heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and
634 family characteristics. *Breast Cancer Res Treat.* Nov 2010;124(1):251-8.
635 doi:10.1007/s10549-010-0853-8
- 636 51. Noh JM, Choi DH, Nam SJ, et al. Characteristics of double heterozygosity
637 for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
638 *Breast Cancer Res Treat.* Jan 2012;131(1):217-22. doi:10.1007/s10549-011-
639 1718-5
- 640 52. Friedman E, Bar-Sade Bruchim R, Kruglikova A, et al. Double
641 heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes.
642 *Am J Hum Genet.* Oct 1998;63(4):1224-7. doi:10.1086/302040
- 643 53. Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S. An unaffected
644 individual from a breast/ovarian cancer family with germline mutations in both
645 BRCA1 and BRCA2. *Clin Genet.* Jan 2000;57(1):70-3. doi:10.1034/j.1399-
646 0004.2000.570111.x
- 647 54. Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in
648 multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
649 *Cancer Res.* May 15 2002;62(10):2741-3.

- 650 55. Thiffault I, Hamel N, Pal T, et al. Germline truncating mutations in both
651 MSH2 and BRCA2 in a single kindred. *Br J Cancer*. Jan 26 2004;90(2):483-91.
652 doi:10.1038/sj.bjc.6601424
- 653 56. Musolino A, Naldi N, Michiara M, et al. A breast cancer patient from Italy
654 with germline mutations in both the BRCA1 and BRCA2 genes. *Breast Cancer*
655 *Res Treat*. May 2005;91(2):203-5. doi:10.1007/s10549-004-7704-4
- 656 57. Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. Germline mutations
657 of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. *Gynecol*
658 *Oncol*. Sep 1998;70(3):432-4. doi:10.1006/gyno.1998.5081
- 659 58. Heidemann S, Fischer C, Engel C, et al. Double heterozygosity for
660 mutations in BRCA1 and BRCA2 in German breast cancer patients: implications
661 on test strategies and clinical management. *Breast Cancer Research and*
662 *Treatment*. Aug 2012;134(3):1229-1239. doi:10.1007/s10549-012-2050-4
- 663 59. Le Page C, Rahimi K, Rodrigues M, et al. Clinicopathological features of
664 women with epithelial ovarian cancer and double heterozygosity for BRCA1 and
665 BRCA2: A systematic review and case report analysis. *Gynecol Oncol*. Feb
666 2020;156(2):377-386. doi:10.1016/j.ygyno.2019.11.019
- 667 60. Sokolenko AP, Bogdanova N, Kluzniak W, et al. Double heterozygotes
668 among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1,
669 and BLM germ-line mutations. *Breast Cancer Res Treat*. Jun 2014;145(2):553-
670 62. doi:10.1007/s10549-014-2971-1
- 671 61. Pern F, Bogdanova N, Schürmann P, et al. Mutation analysis of BRCA1,
672 BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with
673 triple-negative breast cancer. *PLoS One*. 2012;7(10):e47993.
674 doi:10.1371/journal.pone.0047993
- 675 62. Lindor NM, Smyrk TC, Buehler S, et al. Multiple jejunal cancers resulting
676 from combination of germline APC and MLH1 mutations. *Fam Cancer*. Dec
677 2012;11(4):667-9. doi:10.1007/s10689-012-9561-3
- 678 63. Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA
679 testing of breast cancer patients are insufficient to detect all mutation carriers.
680 *BMC cancer*. 2017;17(1):438-438. doi:10.1186/s12885-017-3422-2
- 681 64. Yang S, Axilbund JE, O'Leary E, et al. Underdiagnosis of Hereditary
682 Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss
683 the Mark. *Ann Surg Oncol*. Oct 2018;25(10):2925-2931. doi:10.1245/s10434-
684 018-6621-4
- 685 65. American Society of Clinical Oncology. Statement of the American Society
686 of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on
687 February 20, 1996. *J Clin Oncol*. May 1996;14(5):1730-6; discussion 1737-40.
688 doi:10.1200/JCO.1996.14.5.1730
- 689 66. Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology
690 Expert Statement: collection and use of a cancer family history for oncology
691 providers. *J Clin Oncol*. Mar 10 2014;32(8):833-40.
692 doi:10.1200/JCO.2013.50.9257
- 693 67. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for
694 familial breast cancer incorporating BRCA1, BRCA2 and other genes. *Br J*
695 *Cancer*. Jan 7 2002;86(1):76-83. doi:10.1038/sj.bjc.6600008
- 696 68. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of
697 genetic susceptibility to breast and ovarian cancer. *Br J Cancer*. Oct 18
698 2004;91(8):1580-90. doi:10.1038/sj.bjc.6602175

- 699 69. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for
700 breast cancer-susceptibility genes BRCA1 and BRCA2. *Am J Hum Genet.* Jan
701 1998;62(1):145-58. doi:10.1086/301670
- 702 70. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the
703 chances of identifying a BRCA1/2 mutation outperforms existing models including
704 BRCAPRO. *J Med Genet.* Jun 2004;41(6):474-80. doi:10.1136/jmg.2003.017996
- 705 71. Teixeira N, Maistro S, Del Pilar Estevez Diz M, et al. Predictability of
706 BRCA1/2 mutation status in patients with ovarian cancer: How to select women
707 for genetic testing in middle-income countries. *Maturitas.* Nov 2017;105:113-118.
708 doi:10.1016/j.maturitas.2017.06.002
- 709 72. Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A,
710 Ashton-Prolla P. Recommendations for Advancing the Diagnosis and
711 Management of Hereditary Breast and Ovarian Cancer in Brazil. *JCO Glob Oncol.*
712 2020;6:439-452. doi:10.1200/JGO.19.00170
- 713

714 **Figure legends**

715 Figure 1. Variants profiles. (A) Distribution of patients according to genetic
716 findings. P/LP = patients with pathogenic/likely pathogenic, VUS = patients with
717 variants of uncertain significance (N = 1682). (B) Distribution of P/LP variants per
718 gene. (C) P/LP variants functional annotation. (D) Distribution of VUS per gene.
719 Lynch syndrome genes have been grouped together in (C) and (D).

720

721 Figure 2. Heatmap representing the distribution of pathogenic/likely pathogenic
722 (P/LP) transheterozygotes in the sample. The top line represents the number of
723 patients in each column. The single heterozygotes (n=290) are distributed in the
724 main diagonal. Transheterozygotes (n=15) are distributed in the inferior half (14
725 double-heterozygotes and 1 triple-heterozygote). The total number of variants are
726 321 ($290 \times 1 + 14 \times 2 + 1 \times 3 = 321$).

727

728 **Appendices**

729 **Supplementary Table 1.** Genotyped genes.

730 **Supplementary Table 2.** Ancestry, genetic findings summary, testing criteria,
731 personal and family history.

732 **Supplementary Table 3.** Genetic Findings.

- 733 **Supplementary Table 4.** Positivity rate per gene or combination of genes,
734 alongside number of unique pathogenic/likely pathogenic variants detected in
735 each gene. The variants are detailed for transheterozygotes.
736 **Supplementary Table 5.** Patients per Brazilian state.

Table 1. Demographic and clinical characteristics of Brazilian individuals tested genotyped with NGS hereditary cancer panel.

Demographic	N	%
Sex	1682	100
Female	1557	92.6
Male	125	7.4
<i>Age at diagnosis (years)</i>		
<30	79	4.7
30-40	452	26.9
41-50	526	31.3
51-65	465	27.6
>65	160	9.5
<i>Ethnicity</i>		
Multiple ethnicities (admixed)	330	19.6
White	259	15.4
Black	26	1.5
Jewish Ashkenazi	22	1.3
Native indigenous	21	1.2
Asian	17	1.0
No information	1007	59.9
<i>Personal cancer history †</i>		
Overall	1126	66.9
Breast or ovarian	971	57.7
Colorectal	71	4.2
Thyroid/parathyroid	36	2.1
Prostate	15	0.9
Stomach	14	0.8
Uterus	13	0.8
Kidney	13	0.8
Sarcomas	13	0.8
Leukemia	11	0.6
Skin (non-melanoma)	9	0.5
Pancreas	9	0.5
Other	17	1.0
No cancer history	268	15.9
No information	293	17.4

Family cancer history (first-, second- or third-degree relatives) †

Overall	1182	70.3
Breast or ovarian	973	57.8
Colorectal	310	18.4
Thyroid/parathyroid	108	6.4
Prostate	339	20.2
Stomach	155	9.2
Uterus	122	7.3
Kidney	45	2.7
Sarcomas	22	1.3
Leukemia	139	8.3
Skin (non-melanoma)	72	4.3
Pancreas	83	4.9
Other	235	14.0
No cancer history	163	9.7
No information	337	20.0





† Number of individuals with personal or family history exceeds 1682 because some individuals reported multiple cancer types.

Table 2. NCCN 3.2019/1.2020 and Brazilian ANS testing criteria performance.

Decision	NGS testing		Row totals
	Positive patients	VUS/Negative patients	
<i>NCCN 3.2019/1.2020</i>			
At risk	215	793	1008
No risk	45	323	368
Column totals	260	1116	1376
Insufficient information: 306			
<i>Brazilian ANS</i>			
At risk	145	515	660
No risk	115	576	691
Column totals	260	1091	1351
Insufficient information: 331			

NCCN: sensitivity = 82.7%, specificity = 28.9%, false negative rate = 17.3%, F1-measure = 33.9%.

ANS: sensitivity = 55.8%, specificity = 52.8%, false negative rate = 44.2% F1-measure = 31.5%.

A**B****C****D**

Total 305 patients, 321 P/LP patients

85 45 40 25 16 14 11 8 7 7 6 6 5 4 4 4 2 3 2 1 2 2 0 1 1 1 1 1 1 0 1

